ENTA vs EQ

Enanta Pharmaceuticals, Inc. vs Equillium, Inc. — Valuation Comparison 2026

ENTA

Biotechnology
Enanta Pharmaceuticals, Inc.
Quality
5.1
out of 10
Value Trap
26
LOW
Price
$13.23
Last close
Models
10/13
Active
VS

EQ

Biotechnology
Equillium, Inc.
Quality
6.4
out of 10
Value Trap
24
SAFE
Price
$2.84
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType ENTA Fair ValueENTA Upside EQ Fair ValueEQ Upside
Bayesian DCF Intrinsic $2.32 -82.5% $1.29 -54.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.03 -92.5% $0.05 -97.4%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENTA vs EQ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENTA vs EQ — Which Stock Is More Undervalued?

EQ scores higher with a 6.4/10 quality rating vs ENTA's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Enanta Pharmaceuticals, Inc. (ENTA) and Equillium, Inc. (EQ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENTA currently trades at $13.23 with a QOC of 5.1/10, while EQ trades at $2.84 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).